Results 161 to 170 of about 70,385 (287)

From insights to innovations: evaluating preclinical paradigms in demyelinating disease therapeutics. [PDF]

open access: yesLab Anim (NY)
Karbalaee M   +4 more
europepmc   +1 more source

Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases

open access: yesExperimental Physiology, EarlyView.
Abstract Klotho, a pleiotropic protein initially identified for its role in kidney function, has garnered significant attention for its neuroprotective properties in various neurodegenerative diseases. It regulates key processes, such as oxidative stress, neuroinflammation, synaptic plasticity and myelination, all crucial for maintaining neuronal ...
Amir Arsalan Ghahari   +7 more
wiley   +1 more source

Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report. [PDF]

open access: yesMult Scler J Exp Transl Clin
Khalili R   +3 more
europepmc   +1 more source

A Rare Overlap of AQP4 and MOG Seropositivity in Neuromyelitis Optica Spectrum Disorder: A Case Report

open access: yesClinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
ABSTRACT Background Neuromyelitis optica spectrum disorder (NMOSD) is an immune‐mediated disorder of the central nervous system associated with autoantibodies against aquaporin‐4 (AQP4). This is distinct from myelin‐oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), defined by anti‐MOG antibodies.
Sarah E. Butler   +2 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1494-1506, July 2026.
ABSTRACT Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health‐related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses versus placebo in patients with chronic ITP. ADVANCE SC, a Phase 3, multicenter, randomized, double‐blinded,
Nichola Cooper   +546 more
wiley   +1 more source

Home - About - Disclaimer - Privacy